Cardioneuroablation for Reflex Syncope and Exercise Capacity
NCT ID: NCT06440291
Last Updated: 2025-09-26
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
100 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-05-02
Study Completion Date
2025-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Cardioneuroablation (CNA) is a new promising method to treat reflex syncope which is due to vagally-induced functional sinus arrest or atrio-ventricular block (AVB). Although the procedure is effective in \> 80% of patients, there are potential adverse effects associated with the lack of vagal protection. One of them is increased sinus rate and possible worsening of exercise capacity. However, it is not known how often this happens. Moreover, the most accurate tool to asses exercise capacity - cardiopulmonary exercise testing (CPET), has not yet been used in this group of patients. Therefore, the aim of the study is to assess one-year effects of CNA-induced total vagal denervation on cardiorespiratory fitness in patients undergoing CNA due to reflex asystolic syncope.
The study group consists of patients undergoing CNA in our institution. All patients give informed written consent to undergo CNA and to participate in the study (Ethics Committee approval # 22/2024). CNA is performed according to standard protocol used in our institution. A symptom-limited cardiopulmonary exercise (CPET) is performed twice, at baseline (1-2 days before CNA) and after one year of follow-up. Standard CPET parameters are measured. Quality of life is measured using a dedicated questionnaire. Also, a control group of healthy volunteers will undergo CPET to answer the question whether subjects with reflex syncope differ in exercise capacity from healthy people.
The study group consists of patients undergoing CNA in our institution. All patients give informed written consent to undergo CNA and to participate in the study (Ethics Committee approval # 22/2024). CNA is performed according to standard protocol used in our institution. A symptom-limited cardiopulmonary exercise (CPET) is performed twice, at baseline (1-2 days before CNA) and after one year of follow-up. Standard CPET parameters are measured. Quality of life is measured using a dedicated questionnaire. Also, a control group of healthy volunteers will undergo CPET to answer the question whether subjects with reflex syncope differ in exercise capacity from healthy people.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardioneuroablation for Reflex Syncope
NCT03903744
Syncope, Vasovagal
COMPLETED
NA
Cardioneuroablation and Ventricular Proarrhythmia
NCT06458140
Syncope, Vasovagal
RECRUITING
NA
Assessment of the Durability of Cardioneuroablation Using Physiological Indices of Heart Rate Reactivity
NCT06697145
Syncope, Vasovagal, Neurally-Mediated
COMPLETED
NA
Cardioinhibitory Reflex Syncope. Permanent Pacemaker Therapy or Cardioneuroablation?
NCT05855603
Reflex Syncope
RECRUITING
NA
Efficacy of Transcatheter Ablation Using Anatomic Approach of Ganglionated Plexi Located in the Right Atrium to Prevent Neuromediated Cardioinhibitory Syncope
NCT01814228
Neuromediated Cardioinhibitory Syncope
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Introduction Cardioneuroablation (CNA) is a new promising method to treat reflex syncope which is due to vagally-induced functional sinus arrest or atrio-ventricular block (AVB). The goal of the procedure is to ablate post-ganglionic endings of the parasympathetic part of the autonomic nervous system (ANS), located in ganglionated plexi (GP) in the epicardial fat and in the myocardium. Although both sympathetic and parasympathetic nerves are localized in GPs, the latter ones only barely regenerate. Therefore, CNA-induced damage to the parasympathetic part of GP is greater and more durable than that of the sympathetic part of ANS. Because increased vagal activity is one of the main mechanisms leading to reflex sinus arrest or atrio-ventricular (AV) block, targeting this part of ANS by CNA may prevent recurrences of reflex syncope. Indeed, it has been shown that CNA may be effective in approximately 80-90% of very symptomatic subjects with reflex syncope.
Lack or diminished parasympathetic drive to the heart may be, however, associated with adverse effects. The main complication which is seen shortly and up to one year after CNA is heart rhythm acceleration which may be symptomatic in approximately one-third of patients. In the majority of patients sinus rate gradually slows down over a period of 3-12 months due to partial parasympathetic reinnervation, however, approximately 6-7% of patients remain severely symptomatic and require heart rate slowing agents. Other complaints such as decreased exercise capacity or effort dyspnea can occur in up to 14% of patients and they are usually attributed to faster than needed sinus rate at rest and during exercise.
Although in the vast majority of patients, the above mentioned symptoms are rather mild and do not decrease the patient's acceptance of CNA, in some may decrease the quality of life. Thus, a detailed assessment of the effects of CNA on exercise performance is clinically important. However, to date, no study addressed this issue.
There are several methods to assess exercise performance with cardiopulmonary exercise testing (CPET) being the most accurate and reference tool. It measures cardiorespiratory fitness and physiological responses to aerobic exercise in many conditions. CPET provides a comprehensive evaluation of the respiratory, circulatory, and metabolic responses to exercise that cannot be accurately measured by less precise methods such as standard exercise stress test. Therefore, we have chosen CPET to evaluate the effects of CNA on exercise performance in our patients.
Aim To assess one-year effects of CNA-induced total vagal denervation on cardiorespiratory fitness in patients undergoing CNA due to reflex asystolic syncope.
To compare cardiorespiratory fitness between subjects with reflex syncope and healthy volunteers.
Hypothesis. Cardioneuroablation significantly decreases cardiopulmonary fitness in patients with reflex asystolic syncope.
There are no differences between patients with syncope and healthy people in cardiorespiratory fitness at baseline whereas post-CNA results of CPET are significantly worse in syncope patients versus controls
Methods Patients. The study group will consist of consecutive patients undergoing CNA in our institution. Patients are referred for CNA if they have severe, recurrent symptoms due to reflex syncope with ECG documented asystole \>3 seconds, especially if associated with injury, or recurrent presyncope with persistent reflex bradycardia. The patients have to have a history of ineffective prior non-pharmacological treatment and a positive baseline atropine test (sinus rate acceleration \> 30% and no AV block following 2 mg of intravenous atropine). All patients gave informed written consent to undergo CNA and to participate in the study (Ethics Committee approval # 22/2024).
Control group. This group will consist of healthy volunteers without cardiovascular and other chronic disorders, age- and gender-matched with the CNA group. This group will not undergo CNA.
Cardioneuroablation. The procedure is performed under general anesthesia with muscle relaxation using a 3.5 mm irrigated tip catheter (Navistar ThermoCool SmartTouch) with contact force module and electroanatomical system Carto 3 (Biosense Webster, US). The ablation index is set at 500 except coronary sinus (CS) where the target value is 350. Intracardiac echocardiography (ICE) (Acuson SC2000, Siemens, Germany, AcuNav™ Ultrasound Catheter, Biosense Webster, US) is also used throughout the whole procedure and serves for guiding ablation, including identification of presumed GP areas. The extra cardiac vagal stimulation (ECVS) is performed using two diagnostic catheters positioned in the right and left jugular veins utilizing neurostimulator designed by Dr Pachon (Sao Paulo, Brazil) (pulse amplitude of 1 V/kg body weight up to 70 V, 50 ms width, 50 Hz frequency, delivered over 5 sec). Complete bilateral vagal denervation of both sinus and AV nodes (no sinus arrest, slowing of sinus rate no more than 10% compared with baseline and no AV block with PR interval no longer than at baseline), documented on ECVS, is the end-point of CNA.
Ablation is usually started in the left atrium (LA) at the anterior antrum of the right pulmonary vein where the superior paraseptal GP (SPSGP) is located, followed by ablation of the inferior paraseptal GP (IPSGP) at the floor of LA). Next, these GPs are ablated from the right atrium (RA). If the intraprocedural endpoints of CNA are not achieved by ablation of paraseptal GPs, additional applications in the LA at the sites of superior and postero-lateral LA GPs are performed, followed by applications in CS.
At the end of the procedure, atropine test is performed in order to assess the residual, if present, vagal nerve activity. The value of \< 10% of increase in sinus rate following atropine injection (2 mg iv) will be taken as successful vagal denervation.
Cardiopulmonary exercise testing A symptom-limited cardiopulmonary exercise (CPET) will be performed twice, at baseline and after one year of follow-up, both in the syncope and control patients. Exercise tests will be performed on a treadmill with a cardio-pulmonary system Reynolds Medical. The same load protocol will be used twice for the same patient. All patients will be encouraged to exercise at maximal effort (≥8 points using the 10-point Borg scale). During the exercise test, the patient's clinical status will be monitored. The systolic and diastolic blood pressure will be recorded every 3 minutes of exercise. Heart rate, heart rate reserve (predicted and achieved), chronotropic index and percentage of maximum predicted heart rate at peak exercise will be calculated (3). The maximum predicted heart rate will be calculated as 220-age in years. The heart rate recovery in 1 minute will be assessed. A 12-lead electrocardiogram will be recorded. ECG and heart rate parameters: ischemia, arrhythmia, or conduction disturbances during exercise and recovery will be accessed according to the American Heart Association recommendations.
Ventilatory and gas exchange parameters will be assessed during the test. The peak oxygen uptake (VO2) will be averaged from the highest 30 s of exercise. Maximum predicted oxygen uptake will be calculated according to the Wasserman/Hansen equations. The anaerobic threshold will be calculated using a dual-method approach (V-slope and ventilatory equivalent methods). Other analyzed cardiopulmonary exercise testing parameters will include oxygen uptake to work rate increment ratio (∆O2/∆WR), ventilatory efficiency (VE/VCO2 slope), and breathing reserve at peak exercise, calculated as the percentage of maximum voluntary ventilation: \[(maximum voluntary ventilation - minute ventilation at peak exercise) / maximum voluntary ventilation\] × 100. All exercise tests will be supervised and analyzed according to current guidelines.
Quality of life. Quality of life will be measured using a dedicated questionnaire: The Impact of Syncope on Quality-of-Life Questionnaire University of Calgary. This questionnaire consists of 9 questions with 6 choices and 3 questions with 5 choices. The overall maximum score is 57. The higher the score the poorer the quality of life is.
Statistical analysis. The results are presented as mean±SD or numbers and percentages. Differences between variables are analysed using paired two-sided student t-test for normally distributed continuous variables or U Mann Whitney for not-normally distributed variables. The Chi square test (with Yates correction if appropriate) or exact Fisher test are used to compare qualitative parameters. A Pearson correlation coefficient is used to assess association between CPET values and QoL results. A p value \< 0.05 is considered significant.
Lack or diminished parasympathetic drive to the heart may be, however, associated with adverse effects. The main complication which is seen shortly and up to one year after CNA is heart rhythm acceleration which may be symptomatic in approximately one-third of patients. In the majority of patients sinus rate gradually slows down over a period of 3-12 months due to partial parasympathetic reinnervation, however, approximately 6-7% of patients remain severely symptomatic and require heart rate slowing agents. Other complaints such as decreased exercise capacity or effort dyspnea can occur in up to 14% of patients and they are usually attributed to faster than needed sinus rate at rest and during exercise.
Although in the vast majority of patients, the above mentioned symptoms are rather mild and do not decrease the patient's acceptance of CNA, in some may decrease the quality of life. Thus, a detailed assessment of the effects of CNA on exercise performance is clinically important. However, to date, no study addressed this issue.
There are several methods to assess exercise performance with cardiopulmonary exercise testing (CPET) being the most accurate and reference tool. It measures cardiorespiratory fitness and physiological responses to aerobic exercise in many conditions. CPET provides a comprehensive evaluation of the respiratory, circulatory, and metabolic responses to exercise that cannot be accurately measured by less precise methods such as standard exercise stress test. Therefore, we have chosen CPET to evaluate the effects of CNA on exercise performance in our patients.
Aim To assess one-year effects of CNA-induced total vagal denervation on cardiorespiratory fitness in patients undergoing CNA due to reflex asystolic syncope.
To compare cardiorespiratory fitness between subjects with reflex syncope and healthy volunteers.
Hypothesis. Cardioneuroablation significantly decreases cardiopulmonary fitness in patients with reflex asystolic syncope.
There are no differences between patients with syncope and healthy people in cardiorespiratory fitness at baseline whereas post-CNA results of CPET are significantly worse in syncope patients versus controls
Methods Patients. The study group will consist of consecutive patients undergoing CNA in our institution. Patients are referred for CNA if they have severe, recurrent symptoms due to reflex syncope with ECG documented asystole \>3 seconds, especially if associated with injury, or recurrent presyncope with persistent reflex bradycardia. The patients have to have a history of ineffective prior non-pharmacological treatment and a positive baseline atropine test (sinus rate acceleration \> 30% and no AV block following 2 mg of intravenous atropine). All patients gave informed written consent to undergo CNA and to participate in the study (Ethics Committee approval # 22/2024).
Control group. This group will consist of healthy volunteers without cardiovascular and other chronic disorders, age- and gender-matched with the CNA group. This group will not undergo CNA.
Cardioneuroablation. The procedure is performed under general anesthesia with muscle relaxation using a 3.5 mm irrigated tip catheter (Navistar ThermoCool SmartTouch) with contact force module and electroanatomical system Carto 3 (Biosense Webster, US). The ablation index is set at 500 except coronary sinus (CS) where the target value is 350. Intracardiac echocardiography (ICE) (Acuson SC2000, Siemens, Germany, AcuNav™ Ultrasound Catheter, Biosense Webster, US) is also used throughout the whole procedure and serves for guiding ablation, including identification of presumed GP areas. The extra cardiac vagal stimulation (ECVS) is performed using two diagnostic catheters positioned in the right and left jugular veins utilizing neurostimulator designed by Dr Pachon (Sao Paulo, Brazil) (pulse amplitude of 1 V/kg body weight up to 70 V, 50 ms width, 50 Hz frequency, delivered over 5 sec). Complete bilateral vagal denervation of both sinus and AV nodes (no sinus arrest, slowing of sinus rate no more than 10% compared with baseline and no AV block with PR interval no longer than at baseline), documented on ECVS, is the end-point of CNA.
Ablation is usually started in the left atrium (LA) at the anterior antrum of the right pulmonary vein where the superior paraseptal GP (SPSGP) is located, followed by ablation of the inferior paraseptal GP (IPSGP) at the floor of LA). Next, these GPs are ablated from the right atrium (RA). If the intraprocedural endpoints of CNA are not achieved by ablation of paraseptal GPs, additional applications in the LA at the sites of superior and postero-lateral LA GPs are performed, followed by applications in CS.
At the end of the procedure, atropine test is performed in order to assess the residual, if present, vagal nerve activity. The value of \< 10% of increase in sinus rate following atropine injection (2 mg iv) will be taken as successful vagal denervation.
Cardiopulmonary exercise testing A symptom-limited cardiopulmonary exercise (CPET) will be performed twice, at baseline and after one year of follow-up, both in the syncope and control patients. Exercise tests will be performed on a treadmill with a cardio-pulmonary system Reynolds Medical. The same load protocol will be used twice for the same patient. All patients will be encouraged to exercise at maximal effort (≥8 points using the 10-point Borg scale). During the exercise test, the patient's clinical status will be monitored. The systolic and diastolic blood pressure will be recorded every 3 minutes of exercise. Heart rate, heart rate reserve (predicted and achieved), chronotropic index and percentage of maximum predicted heart rate at peak exercise will be calculated (3). The maximum predicted heart rate will be calculated as 220-age in years. The heart rate recovery in 1 minute will be assessed. A 12-lead electrocardiogram will be recorded. ECG and heart rate parameters: ischemia, arrhythmia, or conduction disturbances during exercise and recovery will be accessed according to the American Heart Association recommendations.
Ventilatory and gas exchange parameters will be assessed during the test. The peak oxygen uptake (VO2) will be averaged from the highest 30 s of exercise. Maximum predicted oxygen uptake will be calculated according to the Wasserman/Hansen equations. The anaerobic threshold will be calculated using a dual-method approach (V-slope and ventilatory equivalent methods). Other analyzed cardiopulmonary exercise testing parameters will include oxygen uptake to work rate increment ratio (∆O2/∆WR), ventilatory efficiency (VE/VCO2 slope), and breathing reserve at peak exercise, calculated as the percentage of maximum voluntary ventilation: \[(maximum voluntary ventilation - minute ventilation at peak exercise) / maximum voluntary ventilation\] × 100. All exercise tests will be supervised and analyzed according to current guidelines.
Quality of life. Quality of life will be measured using a dedicated questionnaire: The Impact of Syncope on Quality-of-Life Questionnaire University of Calgary. This questionnaire consists of 9 questions with 6 choices and 3 questions with 5 choices. The overall maximum score is 57. The higher the score the poorer the quality of life is.
Statistical analysis. The results are presented as mean±SD or numbers and percentages. Differences between variables are analysed using paired two-sided student t-test for normally distributed continuous variables or U Mann Whitney for not-normally distributed variables. The Chi square test (with Yates correction if appropriate) or exact Fisher test are used to compare qualitative parameters. A Pearson correlation coefficient is used to assess association between CPET values and QoL results. A p value \< 0.05 is considered significant.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Syncope, Vasovagal
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cardioneuroablation
Cardioneuroablation procedure as described in the Methods section of the study
Group Type
EXPERIMENTAL
Cardioneuroablation
Intervention Type
PROCEDURE
Cardioneuroablation procedure performed according to the protocol
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cardioneuroablation
Cardioneuroablation procedure performed according to the protocol
Intervention Type
PROCEDURE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* severe, recurrent symptoms due to reflex syncope or recurrent presyncope due to slow heart rate
* ECG documented asystole \>3 seconds
* ineffective prior non-pharmacological treatment
* positive baseline atropine test (sinus rate acceleration \> 30% and no atrio-ventricular block following 2 mg of intravenous atropine)
* signed written informed consent
* ECG documented asystole \>3 seconds
* ineffective prior non-pharmacological treatment
* positive baseline atropine test (sinus rate acceleration \> 30% and no atrio-ventricular block following 2 mg of intravenous atropine)
* signed written informed consent
Exclusion Criteria
* serious comorbidities precluding general anaesthesia and cardioneuroablation
* non-functional sinus arrest or atrio-ventricular block (negative atropine test)
* lack of consent to participate in the study
* non-functional sinus arrest or atrio-ventricular block (negative atropine test)
* lack of consent to participate in the study
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre of Postgraduate Medical Education
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Piotr Kulakowski
Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roman Piotrowski, PhD
Role: STUDY_DIRECTOR
Department of Cardiology, Postgraduate Medical School, Grochowski Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Cardiology, Postgraduate Medical School, Grochowski Hospital
Warsaw, , Poland
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Poland
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Pachon JC, Pachon EI, Pachon JC, Lobo TJ, Pachon MZ, Vargas RN, Jatene AD. "Cardioneuroablation"--new treatment for neurocardiogenic syncope, functional AV block and sinus dysfunction using catheter RF-ablation. Europace. 2005 Jan;7(1):1-13. doi: 10.1016/j.eupc.2004.10.003.
Reference Type
BACKGROUND
Pachon JC, Pachon EI, Cunha Pachon MZ, Lobo TJ, Pachon JC, Santillana TG. Catheter ablation of severe neurally meditated reflex (neurocardiogenic or vasovagal) syncope: cardioneuroablation long-term results. Europace. 2011 Sep;13(9):1231-42. doi: 10.1093/europace/eur163. Epub 2011 Jun 28.
Reference Type
BACKGROUND
Piotrowski R, Baran J, Sikorska A, Krynski T, Kulakowski P. Cardioneuroablation for Reflex Syncope: Efficacy and Effects on Autonomic Cardiac Regulation-A Prospective Randomized Trial. JACC Clin Electrophysiol. 2023 Jan;9(1):85-95. doi: 10.1016/j.jacep.2022.08.011. Epub 2022 Aug 28.
Reference Type
BACKGROUND
Kulakowski P, Baran J, Sikorska A, Krynski T, Niedzwiedz M, Soszynska M, Piotrowski R. Cardioneuroablation for reflex asystolic syncope: Mid-term safety, efficacy, and patient's acceptance. Heart Rhythm. 2024 Mar;21(3):282-291. doi: 10.1016/j.hrthm.2023.11.022. Epub 2023 Nov 29.
Reference Type
BACKGROUND
Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, Forman D, Franklin B, Guazzi M, Gulati M, Keteyian SJ, Lavie CJ, Macko R, Mancini D, Milani RV; American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Peripheral Vascular Disease; Interdisciplinary Council on Quality of Care and Outcomes Research. Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation. 2010 Jul 13;122(2):191-225. doi: 10.1161/CIR.0b013e3181e52e69. Epub 2010 Jun 28. No abstract available.
Reference Type
BACKGROUND
Rose MS, Koshman ML, Ritchie D, Sheldon R. The development and preliminary validation of a scale measuring the impact of syncope on quality of life. Europace. 2009 Oct;11(10):1369-74. doi: 10.1093/europace/eup106.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
501-1-10-14-24
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Cardiac Autonomic Denervation for Cardio-inhibitory Syncope
NCT05572034
UNKNOWN
NA
Cardioneuroablation for Neurocardiogenic Syncope
NCT02009982
COMPLETED
NA
Optimizing Diagnostics Of Syncope Events Using Intelligent Telemetric Solutions.
NCT01265290
UNKNOWN
NA
POLish Registry of CArdioneuroablation and CArdioneuromodulation
NCT07196397
RECRUITING
Vagal Response and Cardiac Autonomic Modulation. Insides From Cryoballoon Ablation
NCT04896424
COMPLETED
NA
National Registry of Cardioneuroablation in Recurrent Reflex Syncope
NCT06159764
RECRUITING
Intracardiac Echocardiography Guided Slow Pathway Cryoablation
NCT05705297
ENROLLING_BY_INVITATION
Comparison of the Efficacy and Safety of Cardioneuroablation to Permanent Pacing in Patients With an Implanted Pacemaker for Symptomatic Bradycardia.
NCT05896592
RECRUITING
NA
Telemetric Arrhythmia and Syncope Diagnosis - Evaluation of Arrhythmia Treatment Efficacy
NCT01265303
UNKNOWN
NA
Modification of Rhythmic Risk Assessment by Ventricular Tachycardia Ablation
NCT03453645
UNKNOWN
Botulinum Toxin Injection to Prevent Ventricular Arrhythmias
NCT02003001
UNKNOWN
PHASE1
Inducibility and Stability of Ventricular Tachycardia Inpatients Undergoing VT Ablation Under General Anesthesia
NCT02419547
COMPLETED
NA
Transcutaneous Vagus Nerve Stimulation for Ventricular Arrhythmias
NCT07026695
NOT_YET_RECRUITING
NA
Impact of Catheter Ablation of Ventricular Arrhythmias on Suboptimal Biventricular Pacing in Cardiac Resynchronization Therapy
NCT04065893
COMPLETED
Preventive VT Substrate Ablation in Ischemic Heart Disease
NCT04675073
RECRUITING
PHASE3
Electrophysiological Mechanisms and Inhibitory Cardiac Syncope
NCT02861274
COMPLETED
PHASE1
Efficacy of a Right-sided Ablation of the Anterior Ganglionated Plexus for Neurally Mediated Syncope
NCT04755101
RECRUITING
NA
Cardioneuroablation for Bradyarrhythmia
NCT06288633
RECRUITING
NA
Impact of Catheter Ablation of Frequent Premature Ventricular Complexes in Treating Subtle Left Cardiomyopathy
NCT06864429
COMPLETED
NA
Cardioneuroablation Versus Pacemaker Implantation for the Treatment of Symptomatic Sinus Node Dysfunction
NCT05186220
UNKNOWN
NA
Recurrent Ventricular Arrythmias in ICU
NCT07033065
NOT_YET_RECRUITING
Comparision of PVC Ablation Techniques
NCT03086902
UNKNOWN
NA
Effect of Closed Loop Pacemaker Treatment on Recurrent Vasovagal Syncope
NCT00292825
COMPLETED
NA
Guideline-based Pacing Therapy for Reflex Syncope
NCT01509534
COMPLETED
Cohort Description of Younger With AV-block
NCT03024047
UNKNOWN